BETHLEHEM, Pa., Feb. 16, 2012 /PRNewswire/ -- Particle Sciences, Inc. (PSI), a leading pharmaceutical CRO, announced today that Robert Gwozdz, M.S. Pharmaceutics, will now be heading PSI's oral formulation efforts. According to Mark Mitchnick, the company's CEO, "PSI has a broad array of drug delivery technologies applicable across many dosage forms and drug types. For instance, about 70% of our work now is on small molecules of which about 80% fall into BCS II. About 25% of our work is on oral products. The client base now warrants a dedicated Director for oral product development. Robert has a vast amount of experience having come from the generics industry and having been key on approximately thirty ANDA's." Robert Gwozdz adds, "Having been with one of the largest generic companies, I have had the luxury of exposure to virtually every current delivery strategy. I'm really looking forward to leveraging PSI's technology portfolio for both new chemical entities and life-cycle extension challenges. The approaches to both these challenges have substantially merged over the last few years and PSI is perfectly positioned to leverage this."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visitwww.particlesciences.com, email firstname.lastname@example.org contact us at (610) 861- 4701 for information.
Contact: Maureen Mattera
SOURCE Particle Sciences, Inc.